A5102795029- Endometrial and Cervical Cancer Treatments
- Ovarian cancer diagnosis and treatment
- Cancer, Lipids, and Metabolism
- Genetic factors in colorectal cancer
- Sarcoma Diagnosis and Treatment
BackgroundPart 1 of the RUBY trial (NCT03981796) evaluated dostarlimab plus carboplatin-paclitaxel compared with placebo in patients primary advanced or recurrent endometrial cancer. At first interim analysis, met one its dual-primary endpoints statistically significant progression-free survival benefits mismatch repair deficient/microsatellite instability–high (dMMR/MSI-H) and overall populations. Overall (OS) results are reported from second analysis.Patients MethodsRUBY is a phase 3,...
At interim analysis (IA) 1 of Part the RUBY trial (NCT03981796), statistically significant benefit in PFS was observed with dostarlimab+carboplatin-paclitaxel (D+CP) vs placebo (PBO)+CP overall and mismatch repair deficient/microsatellite instability-high (dMMR/MSI-H) populations pts pA/rEC. Here we report OS from IA2. Pts pA/rEC were randomized 1:1 to D+CP or PBO+CP followed by D PBO for ≤3 years until progression. a dual-primary endpoint population prespecified, exploratory dMMR/MSI-H...